Shots:
- Sorrento has filed an IND for STI-1499 in patients hospitalized with COVID-19. In preclinical studies, STI-1499 has demonstrated 100% neutralizing effect (in vitro) against the highly contagious D614G mutant strain at a low dose
- Additionally, animal model data confirms the neutralizing profile and high potency of Ab, expected effective dose in human to be at least 5 times lower than current known Abs being assessed in other active trials
- Sorrento has initiated cGMP manufacturing to produce 50,000 doses, expected to be available by the end of 2020, in anticipation of a potential EUA
Click here to read full press release/ article | Ref: Sorrento | Image: Blogger
